Treats secondary hyperparathyroidism. Sold as Calderol, Rayaldee. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Calcifediol (sold as Calderol, Rayaldee), first approved Aug 5, 1980, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Rayaldee | Part D | $37.2M | -13% | 4,528 |
| Vitamin D Status and Asthma Control, Pulmonary Function, and Oxidative Stress in Adults With Bronchial AsthmaBronchial Asthma, Vitamin D Deficiency · Sinai University | — | Not yet recruiting | Jul 29, 2026 |
| Vitamin D Status and Lipid Profile in Obese Adults With Type 2 DiabetesType 2 Diabetes Mellitus, Obesity · Sinai University | — | Not yet recruiting | Jul 27, 2026 |
| Cardiovascular Effects of Parathyroid Hormone Analogues in Chronic HypoparathyroidismChronic Hypoparathyroidism · National and Kapodistrian University of Athens | — | Active, not recruiting | Jul 16, 2026 |
| Vitamin D2 vs Vitamin D2 Plus Calcitriol in Cholestatic Children With Vitamin D DeficiencyCholestatic Liver Disease, Chronic Liver Disease (CLD) · Chulalongkorn University | Phase 4 | Recruiting | Jun 26, 2026 |
| Sleep Quality and Biomarkers in Adolescent Girls With Anorexia NervosaAnorexia Nervosa · University of Split, School of Medicine | — | Not yet recruiting | Jun 12, 2026 |
| ALPCO 25(OH) Vitamin D CLIA Kit - Fresh Versus Frozen Serum and Plasma Stability StudyVitamin D Deficiency, Vitamin D Insufficiency · American Laboratory Products Company | — | Enrolling by invitation | May 4, 2026 |
| IBM Dietary Surveillance StudyInclusion Body Myositis · Manchester Metropolitan University | — | Not yet recruiting | Apr 17, 2026 |
| Exercise Training and Vitamin D MetabolismObesity & Overweight, Vitamin D · University of Thessaly | Not applicable | Recruiting | Dec 23, 2025 |
| Aug 5, 1980 | CalderolNDA 18312 · New molecular entity | Organon USA Inc | 7 | Discontinued |
| Jun 17, 2016 | RayaldeeNDA 208010 · New formulation or manufacturer | Eirgen | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
